Literature DB >> 24253183

[Chemo- versus radiochemotherapy in stage III non-small-cell lung cancer with poor prognosis: the Conrad Study].

C Nieder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24253183     DOI： 10.1007/s00066-013-0490-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.

Authors:  M Guckenberger; A Kavanagh; M Partridge
Journal:  Strahlenther Onkol       Date:  2012-08-31       Impact factor: 3.621

2.  Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.

Authors:  Sergiusz Nawrocki; Maciej Krzakowski; Ewa Wasilewska-Tesluk; Dariusz Kowalski; Monika Rucinska; Rafal Dziadziuszko; Aleksander Sowa
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

3.  Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.

Authors:  Hak Choy; Lee S Schwartzberg; Shaker R Dakhil; Edward B Garon; David E Gerber; Janak K Choksi; Ramaswamy Govindan; Guangbin Peng; Andrew Koustenis; Joseph Treat; Coleman Obasaju
Journal:  J Thorac Oncol       Date:  2013-10       Impact factor: 15.609

4.  Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Authors:  H H Strøm; R M Bremnes; S H Sundstrøm; N Helbekkmo; O Fløtten; U Aasebø
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

5.  Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations.

Authors:  Carsten Nieder; Adam Pawinski; Nicolaus H Andratschke
Journal:  Front Oncol       Date:  2013-07-09       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.